Home›Trial›NCT06483945
NCT06483945RECRUITING

Dexcom Continuous Glucose Monitoring System Use in aReal-World, Global Registry (Dexcom Global Registry)

Study Summary

"To evaluate the use of the Dexcom CGM System when used according to approved commercial labeling during standard clinical use and its impact on intended users in a real-world setting"

Conditions
Diabetes
Interventions / Drugs
Dexcom CGM G6/G6 Pro/G7
View on ClinicalTrials.gov ↗
Sponsor
DXCM
DexCom Inc
Diabetes Tech
F33/100
Study Details
Enrollment5000 participants
Primary Completion—
Lead SponsorDexCom, Inc.
Data Retrieved2026-04-11 04:12:09.450723+00:00
What This Trial Means for Biotech Investors
Trial Phase Context
Status & Expected Data

Currently recruiting: the trial is enrolling patients. A data readout is not expected until after enrollment closes and the follow-up period is complete.

Enrolled: 5,000 participants
Sponsor Catalyst Profile

DexCom Inc (DXCM) is the sponsoring company for this trial. BiotechSign currently grades this company F (33/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.

DXCM Full Pipeline →All Companies →
Not financial advice. BiotechSign data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.